Resources Repository
-
Resource PackWeb Portal, Teaching Resource 2017Resource Pack: Valuing Vaccines and GAVI
This resource pack on valuing vaccines and GAVI was curated by the Center for Health …
This resource pack on valuing vaccines and GAVI was curated by the Center for Health Decision Science to showcase existing information and analyses to motivate students, educators and others to pursue new applications of decision science methods to the public health challenge of vaccine preventable illnesses.
Calibration/Validation | Child/Nutrition | Infectious Diseases | Cost-Effectiveness Analysis | Preferences/Values | Priority Setting/Ethics | Costing Methods | Mathematical Models | Dynamic Transmission | Benefit-Cost Analysis | Health Systems | Global Governance | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | Global | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Policy Translation | Quantitative Literacy -
ArticlePublication 2017Estimated Economic Impact of Vaccinations in 73 LMIC, 2001-2020
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 …
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 vaccine-preventable diseases between 2001 and 2020 in 73 low- and middle-income countries largely supported by Gavi, the Vaccine Alliance. The authors used health impact models to estimate the economic impact of achieving forecasted coverages for vaccination against Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae and yellow fever. In…
Child/Nutrition | Infectious Diseases | Cost-Effectiveness Analysis | Microsimulation | Health Outcomes | State-Transition | Dynamic Transmission | Health Systems | Economics/Finance | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2016Cost-Effectiveness of Diagnosing HIV Infection During Early Infancy in South Africa
In this study the clinical impact and cost-effectiveness of four different early infant HIV diagnosis …
In this study the clinical impact and cost-effectiveness of four different early infant HIV diagnosis (EID) testing strategies for HIV-exposed infants in South Africa were compared using a microsimulation model. The strategies included (1) no EID (diagnosis only after illness), (2) and (3) testing once (at birth alone or at 6 weeks of age alone), and (4) testing twice (at birth and 6 weeks of age). Findings showed that the testing at birth alone strategy…
Child/Nutrition | Infectious Diseases | Cost-Effectiveness Analysis | Microsimulation | Health/Medicine | Sub-Saharan Africa -
ArticlePublication 2015Cost-Effectiveness of First-Line Antiretroviral Therapy for HIV-Infected African Children Less Than 3 Years of Age
This article compares the cost-effectiveness of different strategies of first-line antiretroviral therapy (no ART, first-line nevirapine …
This article compares the cost-effectiveness of different strategies of first-line antiretroviral therapy (no ART, first-line nevirapine with second-line lopinavir/ritonavir, and first-line lopinavir/ritonavir with second-line nevirapine) for HIV-infected children less than 3 years of age in Africa, using the Cost-Effectiveness of Preventing AIDS Complications- Pediatric model and data obtained from the International Maternal, Pediatric, and Adolescent Clinical Trial P1060 trial. Results demonstrated that both ART regimens were very cost-effective compared to no ART. First-line lopinavir/ritonavir led to longer…
Child/Nutrition | Infectious Diseases | Cost-Effectiveness Analysis | Microsimulation | Health/Medicine | Sub-Saharan Africa -
ArticlePublication 2013Validation and Calibration of a Simulation Model of Pediatric HIV Infection
The authors developed a microsimulation model of pediatric HIV disease progression using the Cost-Effectiveness of …
The authors developed a microsimulation model of pediatric HIV disease progression using the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) model framework. This CEPAC-Pediatric model was then validated by varying CD4 data and comparing the corresponding model-generated survival curves to empirical survival curves obtained from the International Epidemiologic Database to Evaluate AIDS (IeDEA). The model was calibrated to other African countries by systematically varying immunologic and HIV mortality-related input parameters. In the calibration analyses, the model-generated…
Calibration/Validation | Child/Nutrition | Infectious Diseases | Microsimulation | Health/Medicine | Sub-Saharan Africa -
ArticlePublication 2009Cost-Effectiveness of Rotavirus Vaccination in Vietnam
This article reports on a cost-effectiveness analysis of rotavirus vaccination, including varying degrees of severity, …
This article reports on a cost-effectiveness analysis of rotavirus vaccination, including varying degrees of severity, age-dependency of clinical manifestation, and additional features of the disease (e.g., the possibility of reinfection and varying degrees of partial immunity conferred by natural infection). The authors developed a Markov model that reflects key features of rotavirus infection, using the most recent data available at the time of their analysis. They applied the model to the 2004 Vietnamese birth cohort…
Calibration/Validation | Child/Nutrition | Infectious Diseases | Cost-Effectiveness Analysis | Mathematical Models | Health Systems | Health/Medicine | Asia & Pacific -
ArticlePublication 2021New Microsimulation Models to Inform Cervical Cancer Control
Health decision models consider the lifetime natural history of human papillomavirus (HPV) infection and pathogenesis …
Health decision models consider the lifetime natural history of human papillomavirus (HPV) infection and pathogenesis of cervical cancer, and estimate the long-term impact of preventive interventions. We propose a new health decision modeling framework that de-emphasizes previously used cytologic-colposcopic-histologic diagnoses, which are subjective and lack reproducibility, relying instead on HPV type and duration of infection as the major determinants of model transition probabilities. We posit that new model health states and corollary transitions are universal,…
Calibration/Validation | Infectious Diseases | Cost-Effectiveness Analysis | Microsimulation | Mathematical Models | Decision Analysis | Global -
Resource PackWeb Portal, Teaching Resource 2018Resource Pack: Cervical Cancer Models
This resource pack, curated by the Center for Health Decision Science, is a collection of …
This resource pack, curated by the Center for Health Decision Science, is a collection of models of HPV-related cervical cancer, differing in design, structure and features based on analytic objectives. In many ways, HPV and its related diseases represent a prototypical public health problem given the communicable and non-communicable nature of disease, opportunities for intervention along the entire disease spectrum (e.g., primary and secondary prevention, diagnosis, treatment), the varied ages at which interventions are targeted…
Calibration/Validation | Infectious Diseases | Cost-Effectiveness Analysis | Microsimulation | Mathematical Models | State-Transition | Dynamic Transmission | Dynamic Simulation | Chronic Disease/Risk | Health Systems | Clinical Care | Business/Industry | Economics/Finance | Health/Medicine | Science/Technology | Global -
ArticlePublication 2011Health and Economic Impact of HPV 16/18 Vaccination and Cervical Cancer Screening in Eastern Africa
In this article the authors use epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe …
In this article the authors use epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe to develop models of HPV-related infection and disease. For each country, they assessed HPV vaccination of girls before age 12 followed by screening with HPV DNA testing once, twice, or three times per lifetime (at ages 35, 40, 45). For women over age 30, they assessed only screening (with HPV DNA testing up to three times per lifetime or VIA…
Calibration/Validation | Infectious Diseases | Cost-Effectiveness Analysis | Microsimulation | Chronic Disease/Risk | Clinical Care | Economics/Finance | Health/Medicine | Science/Technology | Sub-Saharan Africa